Inhibikase Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 14
- Market Cap
- -
- Website
- http://www.inhibikase.com
- Introduction
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.
A PK Study of IkT-148009 in Older and Elderly Healthy Subjects
- Conditions
- Healthy
- Interventions
- Drug: 100mg IkT-148009 WetDrug: 100mg IkT-148009 DryDrug: 50mg IkT-148009 Wet
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Inhibikase Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06644326
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)
- Conditions
- Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Inhibikase Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06643143
A Phase I Dosing Study of IkT-148009.
- Conditions
- Healthy
- Interventions
- Drug: 200mg of Ikt-148009
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- ABLi Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT06641557
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- ABLi Therapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05623774
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- ABLi Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05424276
- Locations
- 🇺🇸
Neurology, Milwaukee, Wisconsin, United States
🇺🇸Neurologist, Boca Raton, Florida, United States
A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients
- Conditions
- Parkinson DiseaseHealthy Elderly
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- ABLi Therapeutics, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT04350177
- Locations
- 🇺🇸
Quest Research Institute LLC, Farmington Hills, Michigan, United States
🇺🇸Collaborative Neuroscience Research, LLC, Long Beach, California, United States
🇺🇸Hassman Research Institute, Marlton, New Jersey, United States